Business, energy, technology, markets and global industry news from Business News Today

precision psychiatry

PharmaDeviceNews precision psychiatry
Representative image of EEG-guided brain stimulation as Wave Neuroscience’s MeRT FDA clearance puts biomarker-led PTSD treatment, neuromodulation, and precision psychiatry under sharper focus.
Medical Devices & Diagnostics

Wave Neuroscience FDA clearance puts EEG-guided PTSD treatment closer to clinical adoption

Find out how Wave Neuroscience’s MeRT FDA clearance could reshape biomarker-guided PTSD treatment and precision psychiatry.

Read More
Representative image: A blood-based mRNA biomarker test could mark a turning point for objective psychiatric diagnostics as Laguna Diagnostics advances its FDA breakthrough-designated tool to help clinicians differentiate schizophrenia from bipolar I disorder.
Medical Devices & Diagnostics

Why the FDA breakthrough pathway matters for Laguna Diagnostics’ psychiatric test

Psychiatry needs objective diagnostics. Laguna Diagnostics now faces the harder test: proving mRNA biomarkers can scale in real care.

Read More
Pharma & Biotech

What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia

Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.

Read More
Pharma & Biotech

Can Alto Neuroscience’s ALTO-101 finally move the needle on cognitive impairment in schizophrenia?

Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in CIAS. Discover what the upcoming data could mean for precision psychiatry.

Read More
Pharma & Biotech

HMNC Brain Health reports Phase 2b efficacy signals for BH-200 in genetically defined depression patients at ACNP

Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reveal genetic responder signals that could advance precision psychiatry in depression treatment.

Read More